图文详情
Camidanlumab (HuMax-TAC), a CD25 monoclonal antibody, selectively binds to the cell-surface antigen CD25, prevalent on numerous hematological tumors but minimally present on normal tissues. This specificity facilitates its use in developing antibody-drug conjugates (ADCs) aimed at treating diseases such as lymphoma and leukemia [1].